Proteins

Product Data Sheet

SR7826

Cat. No.: HY-19353 CAS No.: 1219728-20-7 Molecular Formula: $C_{22}H_{21}N_{5}O_{2}$ Molecular Weight: 387.43

Target: LIM Kinase (LIMK)

Pathway: Cell Cycle/DNA Damage

Powder -20°C Storage: 3 years 2 years

In solvent -80°C 6 months

-20°C 1 month

SOLVENT & SOLUBILITY

In Vitro

DMSO: 100 mg/mL (258.11 mM; Need ultrasonic)

Preparing Stock Solutions	Solvent Mass Concentration	1 mg	5 mg	10 mg
	1 mM	2.5811 mL	12.9056 mL	25.8111 mL
	5 mM	0.5162 mL	2.5811 mL	5.1622 mL
	10 mM	0.2581 mL	1.2906 mL	2.5811 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

- 1. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: 2.5 mg/mL (6.45 mM); Suspended solution; Need ultrasonic
- 2. Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 2.5 mg/mL (6.45 mM); Clear solution

BIOLOGICAL ACTIVITY

Description SR7826 is a class of bis-aryl urea derived potent, selective and orally active LIM kinase (LIMK) inhibitor with an IC₅₀ of 43 nM for LIMK1. SR7826 is >100-fold more selective for LIMK1 than ROCK and JNK kinases^[1].

IC₅₀ & Target LIMK1 **ROCKI** ROCKII 43 nM (IC₅₀) 5536 nM (IC₅₀) 6565 nM (IC₅₀)

In Vitro

In the profiling against a panel of 61 kinases, SR7826 (compound 18b) at 1 μM inhibits only Limk1 and STK16 with ≥80% inhibition. SR7826 is highly efficient in inhibiting cell-invasion/migration in PC-3 cells. SR7826 (compound 18b) inhibits cofilin phosphorylation in A7r5 (IC₅₀ = 470 nM) and PC-3 cells (IC₅₀ < 1 μ M)^[1]. SR7826 (1 µM) inhibits contractions of prostate strips, which were induced by electrical field stimulation and inhibits cofilin phosphorylation in prostate tissues and cultured stromal cells (WPMY-1). In WPMY-1 cells, SR7826 causes breakdown of actin filaments and reduced viability $^{[3]}$.

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

SR7826 (10 mg/kg; oral gavage; once daily; for 11 days; hAPPJ20 mice) treatment significantly reduces the phosphorylation of cofilin at Ser3. SR7826 also increases both apical and basal thin spine density significantly in hAPPJ20 mice over mock-treated animals^[2].

The plasma pharmacokinetics studies on rats are investigated. After intravenous injection, the PK properties of SR7826 (compound 18b; 1mg/kg) with a Cl of 5.2 mL/min/kg, a $T_{1/2}$ of 2.2h, an AUC of 8.4 μ M*h and a C_{max} of 7.7 μ M, and has 36% oral bioavailability in rats (oral administration; 2mg/kg)^[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	hAPPJ20 mice (6-mouth-old) ^[2]	
Dosage:	10 mg/kg	
Administration:	Oral gavage; once daily; for 11 days	
Result:	Significantly reduced the phosphorylation of cofilin at Ser3, a LIMK1 substrate.	

REFERENCES

- [1]. Yan Yin, et al. Bis-aryl urea derivatives as potent and selective LIM kinase (Limk) inhibitors. J Med Chem. 2015 Feb 26;58(4):1846-61.
- [2]. Benjamin W Henderson, et al. Pharmacologic inhibition of LIMK1 provides dendritic spine resilience against β-amyloid. Sci Signal. 2019 Jun 25;12(587):eaaw9318.
- [3]. Qingfeng Yu, et al. Inhibition of human prostate smooth muscle contraction by the LIM kinase inhibitors, SR7826 and LIMKi3. Br J Pharmacol. 2018 Jun;175(11):2077-2096.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898 Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA